Volume 103, June 2016, Pages 1–12
Research paper
- a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
- b School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK
- c Hot Lab. Center, Atomic Energy Authority, Cairo, Egypt
- Received 15 December 2015, Revised 22 March 2016, Accepted 23 March 2016, Available online 25 March 2016
Abstract
A
challenging disease such as lung cancer requires the combination of
different modalities to achieve beneficial therapeutic outcomes. In this
work, PLGA nanoparticles were chosen as colloidal carrier for two drugs
with reported anti-lung cancer activity: naringin and celecoxib. PLGA
nanoparticles were prepared and characterized for their particle size,
zeta potential, entrapment efficiency, in vitro release,
stability, morphology, cytotoxicity, as well as aerosolization and
nebulization behaviors. Their biodistribution pattern upon pulmonary
aerosolization, and safety on healthy lung tissues were determined as
well. Results showed that the described system displayed a particle size
<260 nm with unimodal distribution, entrapment efficiency for
celecoxib and naringin reaching 96% and 62% respectively and a
controlled release profile for the two drugs. The selected formula
displayed favorable nebulization properties with high drug deposition
percentages in lower impinger and impactor stages. It also exhibited
higher cytotoxic activity on A549 lung cancer cell lines compared to the
free drugs combination, while displaying considerable safety on healthy
lung tissues. Biodistribution studies delineated the lung deposition
potential of the nanoparticles accompanied with high distribution to the
bones, brain and liver which are common metastatic sites of lung
cancer, proving their promising nature in the treatment of lung cancer.
Graphical abstract
Chemical compounds studied in this article
- Poly (lactide-co-glycolide) (PubChem CID: 71391);
- Polyvinyl alcohol (PubChem CID: 11199);
- Poloxamer 188 (PubChem CID: 24751);
- Naringin (PubChem CID: 442428);
- Celecoxib (PubChem CID: 2662)
Keywords
- Air jet nebulizer;
- Next generation impactor;
- Anticancer COX-2 inhibitor;
- Herbal anticancer;
- Delivery system
Copyright © 2016 Elsevier B.V. All rights reserved.
